mint-cefprozil tablet
mint pharmaceuticals inc - cefprozil (cefprozil monohydrate) - tablet - 250mg - cefprozil (cefprozil monohydrate) 250mg - second generation cephalosporins
mint-cefprozil tablet
mint pharmaceuticals inc - cefprozil (cefprozil monohydrate) - tablet - 500mg - cefprozil (cefprozil monohydrate) 500mg - second generation cephalosporins
pravastatin tablets
ranbaxy pharmaceuticals canada inc. - pravastatin sodium - tablet - 10mg - pravastatin sodium 10mg - hmg-coa reductase inhibitors
pravastatin tablets
ranbaxy pharmaceuticals canada inc. - pravastatin sodium - tablet - 20mg - pravastatin sodium 20mg - hmg-coa reductase inhibitors
pravastatin tablets
ranbaxy pharmaceuticals canada inc. - pravastatin sodium - tablet - 40mg - pravastatin sodium 40mg - hmg-coa reductase inhibitors
prostapet- chimaphila umbellata whole, saw palmetto liquid
groupe cyrenne inc. - chimaphila umbellata whole (unii: wck21a9w9j) (chimaphila umbellata - unii:wck21a9w9j), saw palmetto (unii: j7wwh9m8qs) (saw palmetto - unii:j7wwh9m8qs) - chimaphila umbellata 30k large prostate sabal serrulata 30k enlarged prostate helps promote prostate health. for cats and dogs only.
keppra
ucb pharma sa - levetiracetam - epilepsy - antiepileptics, - keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
vimpat
ucb pharma sa - lacosamide - epilepsy - antiepileptics, - vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
lacosamide ucb
ucb pharma s.a. - lacosamide - epilepsies, partial - antiepileptics, - lacosamide ucb is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetam - epilepsy - antiepileptics, - briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.